Literature DB >> 27738784

Venous thromboembolism in chronic kidney disease: epidemiology, the role of proteinuria, CKD severity and therapeutics.

Chrisanna Dobrowolski1, Edward G Clark2, Manish M Sood3,4.   

Abstract

The worldwide prevalence of chronic kidney disease is 10-15 % of the adult population, is rising and increases susceptibility to venous thromboembolism (VTE). In this narrative review we discuss the underlying evidence behind the association of VTE/CKD and examine the role of worsening CKD stage, proteinuria, and the risk of recurrent VTE. As CKD may alter therapeutic options we discuss the role of emerging therapies, the non-vitamin K oral anticoagulants (NOAC), in the treatment of VTE.

Entities:  

Keywords:  Albuminuria; Chronic kidney disease; Epidemiology; Non-vitamin K antagonist oral anticoagulants; Venous thromboembolism

Mesh：

Substances：

Year:  2017        PMID： 27738784     DOI： 10.1007/s11239-016-1437-1

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


  38 in total

1.  Cystatin C is associated with risk of venous thromboembolism in subjects with normal kidney function--the Tromsø study.

Authors:  Ellen E Brodin; Sigrid K Brækkan; Anders Vik; Jan Brox; John-Bjarne Hansen
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 2.  Microparticles and microRNAs: new players in the complex field of coagulation.

Authors:  Claudia Camaioni; Massimo Gustapane; Pio Cialdella; Roberta Della Bona; Luigi Marzio Biasucci
Journal:  Intern Emerg Med       Date:  2011-10-28       Impact factor: 3.397

3.  Cystatin C versus creatinine in determining risk based on kidney function.

Authors:  Michael G Shlipak; Kunihiro Matsushita; Johan Ärnlöv; Lesley A Inker; Ronit Katz; Kevan R Polkinghorne; Dietrich Rothenbacher; Mark J Sarnak; Brad C Astor; Josef Coresh; Andrew S Levey; Ron T Gansevoort
Journal:  N Engl J Med       Date:  2013-09-05       Impact factor: 91.245

Review 4.  Epidemiology of venous thromboembolism.

Authors:  John A Heit
Journal:  Nat Rev Cardiol       Date:  2015-06-16       Impact factor: 32.419

5.  Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

Authors:  Stuart J Connolly; Truman J Milling; John W Eikelboom; C Michael Gibson; John T Curnutte; Alex Gold; Michele D Bronson; Genmin Lu; Pamela B Conley; Peter Verhamme; Jeannot Schmidt; Saskia Middeldorp; Alexander T Cohen; Jan Beyer-Westendorf; Pierre Albaladejo; Jose Lopez-Sendon; Shelly Goodman; Janet Leeds; Brian L Wiens; Deborah M Siegal; Elena Zotova; Brandi Meeks; Juliet Nakamya; W Ting Lim; Mark Crowther
Journal:  N Engl J Med       Date:  2016-08-30       Impact factor: 91.245

6.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

7.  Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey.

Authors:  Paul Arora; Priya Vasa; Darren Brenner; Karl Iglar; Phil McFarlane; Howard Morrison; Alaa Badawi
Journal:  CMAJ       Date:  2013-05-06       Impact factor: 8.262

8.  Microalbuminuria and risk of venous thromboembolism.

Authors:  Bakhtawar K Mahmoodi; Ron T Gansevoort; Nic J G M Veeger; Abigail G Matthews; Gerjan Navis; Hans L Hillege; Jan van der Meer
Journal:  JAMA       Date:  2009-05-06       Impact factor: 56.272

Review 9.  Haemostasis in chronic kidney disease.

Authors:  Jens Lutz; Julia Menke; Daniel Sollinger; Helmut Schinzel; Klaus Thürmel
Journal:  Nephrol Dial Transplant       Date:  2013-10-16       Impact factor: 5.992

Review 10.  The epidemiology of venous thromboembolism.

Authors:  John A Heit; Frederick A Spencer; Richard H White
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300
View more
  7 in total

1.  Potential Pathogenesis and Biomarkers of Kidney Cancer-Related Stroke.

Authors:  Haihong Jiang; Chao Qin; Daobin Cheng; Qiuhong Lu; Gelun Huang; Dacheng Wang; Hong Yang; Zhijian Liang
Journal:  Med Sci Monit       Date:  2017-05-15

2.  Increased risk of deep vein thrombosis in end-stage renal disease patients.

Authors:  Hsueh-Yi Lu; Kuang-Ming Liao
Journal:  BMC Nephrol       Date:  2018-08-16       Impact factor: 2.388

3.  Venous thromboembolism prophylaxis in inflammatory bowel disease flare-ups.

Authors:  Osama Kaddourah; Laith Numan; Sravan Jeepalyam; Omar Abughanimeh; Mouhanna Abu Ghanimeh; Khalil Abuamr
Journal:  Ann Gastroenterol       Date:  2019-08-31

4.  Estrogen and estrogen receptors in kidney diseases.

Authors:  Hao-Yang Ma; Shuang Chen; Yang Du
Journal:  Ren Fail       Date:  2021-01-01       Impact factor: 2.606

5.  Proteinuria and venous thromboembolism in pregnancy: a population-based cohort study.

Authors:  Ayub Akbari; Elizabeth Kunkel; Sarah E Bota; Ziv Harel; Gregoire Le Gal; Conor Cox; Gregory L Hundemer; Mark Canney; Edward Clark; David Massicotte-Azarniouch; Anan Bader Eddeen; Greg Knoll; Manish M Sood
Journal:  Clin Kidney J       Date:  2021-01-11

Review 6.  Health risk of travel for chronic kidney disease patients.

Authors:  Yoshitaka Furuto; Mariko Kawamura; Akio Namikawa; Hiroko Takahashi; Yuko Shibuya
Journal:  J Res Med Sci       Date:  2020-03-18       Impact factor: 1.852

Review 7.  Thrombolome and Its Emerging Role in Chronic Kidney Diseases.

Authors:  Justyna Fryc; Beata Naumnik
Journal:  Toxins (Basel)       Date:  2021-03-18       Impact factor: 4.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.